These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

961 related items for PubMed ID: 29705182

  • 1. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z, Chen Y, Wang S, Li P, Zhou G, Yuan Y.
    Cancer Lett; 2018 Aug 01; 428():77-89. PubMed ID: 29705182
    [Abstract] [Full Text] [Related]

  • 2. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G, Sun Y, Hong R, Xiong J, Lu Y, Liu Y, Lu J, Zhang Z, Guo C, Nan Y, Huang Q.
    Clin Transl Oncol; 2020 Aug 01; 22(8):1252-1262. PubMed ID: 31865606
    [Abstract] [Full Text] [Related]

  • 3. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH, Jiao BH, Wang CY, Wu JL.
    CNS Neurosci Ther; 2021 May 01; 27(5):552-563. PubMed ID: 33460245
    [Abstract] [Full Text] [Related]

  • 4. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X.
    Int J Oncol; 2016 Feb 01; 48(2):559-68. PubMed ID: 26648123
    [Abstract] [Full Text] [Related]

  • 5. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage.
    Huang G, Ouyang M, Xiao K, Zhou H, Zhong Z, Long S, Li Z, Zhang Y, Li L, Xiang S, Ding X.
    Life Sci; 2024 Nov 15; 357():123111. PubMed ID: 39369843
    [Abstract] [Full Text] [Related]

  • 6. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR, Guo CC, Yu YJ, Yu ZH, Cai HP, Wu WC, Ma JX, Chen FR, Wang J, Chen ZP.
    Cancer Chemother Pharmacol; 2020 Dec 15; 86(6):773-782. PubMed ID: 33074386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
    Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Galán-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, Zhao J, Kim H, Rodriguez-Perales S, Nam DH, Verhaak RGW, Rabadan R, Jiang T, Wang J, Squatrito M.
    Nat Commun; 2020 Aug 04; 11(1):3883. PubMed ID: 32753598
    [Abstract] [Full Text] [Related]

  • 14. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T, Tsuji S, Nakamura S, Egashira Y, Shimazawa M, Nakayama N, Yano H, Iwama T, Hara H.
    J Neurosurg; 2021 Mar 01; 134(3):701-710. PubMed ID: 32168477
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.
    Cancer Lett; 2013 Apr 30; 331(1):68-75. PubMed ID: 23246370
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S.
    Mol Cancer Ther; 2012 Jun 30; 11(6):1289-99. PubMed ID: 22532597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.